Chapters Transcript Video Trial 20-153: SACI-IO for Hormone Receptor Positive Metastatic Breast Cancer Why test the combination of Trodelvy and pembrolizumab? Previous efforts testing immunotherapy for HR+ breast cancer has shown disappointing results. Hello. My name is Philip Collins and I am a breast medical oncologist at Dana Farber. And I'd like to talk to you about a trial for patients with hormone receptor positive metastatic breast cancer. In this trial we are looking at the role of success to zoom app. Govt can with or without embolism app for patients with media when positive hormone receptor positive her two negative metastatic breast cancer. And before we talk more about the clinical trial, I would like to tell you about 62s. A mob govt can commonly called as well as anyone 32 or traditional v that it's the commercial name. So sexy to Sin mob Govt can is an antibody drug conjugate its that some of you might have heard as smart bombs. And these drugs this class of drugs are commonly called smart bombs because they are able to deliver very effective chemotherapies linked to an antibody that directs the chemotherapy to the cancer cells. Their ways saving the non cancer cells from many of the side effects associated with these very effective chemotherapies. In the case of sexy to zoom app, the chemotherapy is as N 38 that it's linked to an anti troop to antibody and Troop two is a protein commonly expressed on many solid cancers including metastatic breast cancer. Why should we test the combination of traditional V. With embolism up? Well, previous efforts testing immunotherapy for hormone receptor positive breast cancer have been disappointing and regarding the use of trade LV for patients with hormone receptor positive breast cancer. About one third of these patients whose disease has previously worse than on chemotherapy. Do experience tumor shrinkage. We tried LV. In addition, laboratory based studies have suggested that road LV. May make us more sensitive to immunotherapy. So this study is testing whether adding temporal is a map that it's a type of immunotherapy to trade LV is more effective than traditional V. By itself. So here is the trial design on this study, patients with hormone receptor positive metastatic breast cancer whose tumors are Pd L one positive can be enrolled and are randomized to receive succeed to some mob with embolism app or sexy to Zuma vallone and patients can remain on study until progression or if they develop toxicity to any of these drugs that it's not tolerable. So here are some key inclusion and exclusion criteria that tell you whether you might be a suitable candidate for this trial and I will highlight the criteria that are involved. So in order to be able to go on trial, as I mentioned before, the tur needs to be PD L one positive. Using the 22 C three assay, patients might have received prior horn, no therapies and patients can only go on trial if they received either no chemotherapy lines for metastatic disease or one chemotherapy line. In terms of key exclusion criteria, patients who previously received immune checkpoint innovators or sexy to sin mob or any similar drug would not be able to go on trial. So in conclusion, if you are interested to learn more about this trial, ask your oncologist about this trial or any other clinical trial options and we usually recommend that you bring this up when considering a change of treatment, meaning that your scans show that the current treatment is no longer working. If you are not a dana Farber patient, you can contact our new patient coordinator office and tell them that you are interested in a consultation to learn more about possible clinical trials. If you are already a patient at Dana Farber, talk to your oncology team about this trial, that may be a good option for you. And finally, I've listed here our websites where you can find more information about this trial and other trials currently open at Dana Farber. Thank you very much for your attention. Published March 26, 2021 Created by Related Presenters Filipa Lynce, MD Medical Oncology Dr. Lynce received her medical degree from the Universidade Nova de Lisboa, Portugal in 2004. View Profile
